A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752 · clinicaltrials.gov ↗

RECRUITING

Status

2000

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis
Multiple Sclerosis

Interventions

OTHER: No Intervention

Sponsor

TG Therapeutics, Inc.